Tuberculosis Miliary in Patients Treated With Bacillus Calmette-Guerin Immunotherapy: Case Report

Marta Batista, Carlos Alves, Carlos Boinas, Elvira Camacho


Bacillus Calmette-Guerin (BCG), a live attenuated form of Mycobacterium bovis (M. bovis), is the most effective intravesical agent in the treatment of non-invasive bladder cancer. This therapy can cause minor complications like urinary frequency, fever, dysuria and hematuria, but it can also cause more serious systemic complications such as hepatitis, pneumonitis and sepsis. Miliary tuberculosis is a very rare complication of BCG immunotherapy and is associated to high mortality, thus this diagnosis must be early considered and early treatment should be implemented. The authors report a case of miliary tuberculosis after treatment with intravesical BCG, with isolation of M. bovis. The patient presented clinical and imaging improvement after initiation of tuberculostatic agents.

J Med Cases. 2017;8(7):233-235


Miliary tuberculosis; Mycobacterium bovis

Full Text: HTML PDF

Browse  Journals  


Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics


World Journal of Oncology

Gastroenterology Research

Journal of Hematology


Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity


Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research


Journal of Neurology Research

International Journal of Clinical Pediatrics



Journal of Medical Cases, monthly, ISSN 1923-4155 (print), 1923-4163 (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)

This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website:   editorial contact:
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.